Company Description
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States.
Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.
The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016.
BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Cuong Viet Do M.B.A. |
Contact Details
Address: 680 W Nye Lane, Suite 201 Carson City, Nevada 89703 United States | |
| Phone | 775-888-3162 |
| Website | bioviepharma.com |
Stock Details
| Ticker Symbol | BIVI |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001580149 |
| CUSIP Number | 09074F207 |
| ISIN Number | US09074F2074 |
| Employer ID | 46-2510769 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Cuong Viet Do M.B.A. | President, Chief Executive Officer and Director |
| Joanne Wendy Kim CPA | Chief Financial Officer, Treasurer and Corporate Secretary |
| Dr. Joseph M. Palumbo M.D. | Executive Vice President of Research & Development and Chief Medical Officer |
| Clarence N. Ahlem | Senior Vice President of Operations |
| Dr. Penelope Markham Ph.D. | Senior Vice President of Liver Disease Program |
| Denise Smith | Senior Vice President of Manufacturing and Development |
| Dr. Christopher L. Reading Ph.D. | Senior Vice President of Alzheimer's Disease Program |
| Sarah Overton Hoit | Chief Social Impact Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | 8-K | Current Report |
| Mar 11, 2024 | 8-K | Current Report |
| Mar 6, 2024 | 8-K | Current Report |
| Mar 4, 2024 | 8-K/A | [Amend] Current report |
| Mar 4, 2024 | 424B5 | Filing |
| Mar 4, 2024 | 8-K | Current Report |
| Mar 1, 2024 | 424B5 | Filing |
| Mar 1, 2024 | 8-K | Current Report |
| Feb 13, 2024 | 10-Q | Quarterly Report |
| Jan 25, 2024 | 8-K | Current Report |